These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 35688266)

  • 1. CpG-ODN formulated with a nanostructure as adjuvant for anticrotalic serum production. Studies in mice.
    Fusco LS; Pascual MM; Hernandez D; Vallecillo MFS; Arrieta MB; Moron G; Palma S; Maletto BA; Leiva LC
    Toxicon; 2022 Aug; 215():28-36. PubMed ID: 35688266
    [No Abstract]   [Full Text] [Related]  

  • 2. Corrigendum to "CpG-ODN formulated with a nanostructure as adjuvant for anticrotalic serum production. Studies in mice" [Toxicon 215 (2022) 28-36].
    Fusco LS; Pascual MM; Hernandez D; Sánchez Vallecillo MF; Arrieta MB; Moron G; Palma S; Maletto BA; Leiva LC
    Toxicon; 2022 Sep; 216():114. PubMed ID: 35841861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant activity of CpG-ODN formulated as a liquid crystal.
    Sánchez Vallecillo MF; Ullio Gamboa GV; Palma SD; Harman MF; Chiodetti AL; Morón G; Allemandi DA; Pistoresi-Palencia MC; Maletto BA
    Biomaterials; 2014 Mar; 35(8):2529-42. PubMed ID: 24382332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Class-B CpG-ODN Formulated With a Nanostructure Induces Type I Interferons-Dependent and CD4
    Chiodetti AL; Sánchez Vallecillo MF; Dolina JS; Crespo MI; Marin C; Schoenberger SP; Allemandi DA; Palma SD; Pistoresi-Palencia MC; Morón G; Maletto BA
    Front Immunol; 2018; 9():2319. PubMed ID: 30364187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymeric antigen BLSOmp31 formulated with class B CpG-ODN in a nanostructure (BLSOmp31/CpG-ODN/Coa-ASC16) administered by parenteral or mucosal routes confers protection against Brucella ovis in Balb/c mice.
    Moran MC; Bence AR; Vallecillo MFS; Lützelschwab CM; Rodriguez MG; Pardo R; Goldbaum FA; Zylberman V; Palma SD; Maletto BA; Estein SM
    Res Vet Sci; 2021 Mar; 135():217-227. PubMed ID: 33631456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A liquid crystal of ascorbyl palmitate, used as vaccine platform, provides sustained release of antigen and has intrinsic pro-inflammatory and adjuvant activities which are dependent on MyD88 adaptor protein.
    Sánchez Vallecillo MF; Minguito de la Escalera MM; Aguirre MV; Ullio Gamboa GV; Palma SD; González-Cintado L; Chiodetti AL; Soldano G; Morón G; Allemandi DA; Ardavín C; Pistoresi-Palencia MC; Maletto BA
    J Control Release; 2015 Sep; 214():12-22. PubMed ID: 26188153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved biodistribution and enhanced immune response of subunit vaccine using a nanostructure formed by self-assembly of ascorbyl palmitate.
    Marin C; Ruiz Moreno FN; Sánchez Vallecillo MF; Pascual MM; Dho ND; Allemandi DA; Palma SD; Pistoresi-Palencia MC; Crespo MI; Gomez CG; Morón G; Maletto BA
    Nanomedicine; 2024 Jun; 58():102749. PubMed ID: 38719107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery.
    Diwan M; Elamanchili P; Cao M; Samuel J
    Curr Drug Deliv; 2004 Oct; 1(4):405-12. PubMed ID: 16305402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Vaccine Based on Kunitz-Type Molecule Confers Protection Against
    Silvane L; Celias DP; Romagnoli PA; Maletto BA; Sanchez Vallecillo MF; Chiapello LS; Palma SD; Allemandi DA; Sanabria REF; Pruzzo CI; Motrán CC; Cervi L
    Front Immunol; 2020; 11():2087. PubMed ID: 33193292
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major.
    Stacey KJ; Blackwell JM
    Infect Immun; 1999 Aug; 67(8):3719-26. PubMed ID: 10417129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single injection of 19 kda carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 (PyMSP1(19)) formulated with Montanide ISA and CpG ODN induces protective immune response in mice.
    Hirunpetcharat C; Mahakunkijcharoen Y; Jeamwattanalert P; Kittigul L; Mahannop P; Pichyangkul S
    Asian Pac J Allergy Immunol; 2011 Sep; 29(3):252-9. PubMed ID: 22053595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
    Tada R; Muto S; Iwata T; Hidaka A; Kiyono H; Kunisawa J; Aramaki Y
    BMC Res Notes; 2017 Jan; 10(1):68. PubMed ID: 28126014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine.
    Oumouna M; Mapletoft JW; Karvonen BC; Babiuk LA; van Drunen Littel-van den Hurk S
    J Virol; 2005 Feb; 79(4):2024-32. PubMed ID: 15681404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein.
    Ioannou XP; Gomis SM; Karvonen B; Hecker R; Babiuk LA; van Drunen Littel-van den Hurk S
    Vaccine; 2002 Nov; 21(1-2):127-37. PubMed ID: 12443671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies.
    Chu RS; McCool T; Greenspan NS; Schreiber JR; Harding CV
    Infect Immun; 2000 Mar; 68(3):1450-6. PubMed ID: 10678959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
    Mutwiri G; Benjamin P; Soita H; Babiuk LA
    Vaccine; 2008 May; 26(22):2680-8. PubMed ID: 18430493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria-tetanus-pertussis vaccine.
    Sugai T; Mori M; Nakazawa M; Ichino M; Naruto T; Kobayashi N; Kobayashi Y; Minami M; Yokota S
    Vaccine; 2005 Nov; 23(46-47):5450-6. PubMed ID: 16006019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution.
    McCluskie MJ; Weeratna RD; Davis HL
    Mol Med; 2000 Oct; 6(10):867-77. PubMed ID: 11126201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CpG oligodeoxynucleotide vaccination suppresses IgE induction but may fail to down-regulate ongoing IgE responses in mice.
    Peng Z; Wang H; Mao X; HayGlass KT; Simons FE
    Int Immunol; 2001 Jan; 13(1):3-11. PubMed ID: 11133829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
    Tewary P; Sukumaran B; Saxena S; Madhubala R
    Vaccine; 2004 Aug; 22(23-24):3053-60. PubMed ID: 15297055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.